Title: Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease
receiving different sequences of first- and second-line biologic treatments: findings from
ROTARY
Version: 0 Date: 19 Dec 2023
Reviewer's report:
In a clinical practice setting, patients tend to worry about complications that they might develop
from the prescribed medication. Providers have to balance patient care by assessing both efficacy
and safety. Efficacy is less than 50% for almost all advanced treatment options and therefore,
patients tend to get exposed to at least two medications. How sequence impacts long term
efficacy and safety has been of great interest to providers.
In this manuscript, adverse outcomes are described in treatment sequence and findings are
notable and include risk of dysplasia and CRC.
One limitation is that the evaluable sample size is different for each of the 6 sequences. Authors
do not comment about this in the limitation section lines 333 to 343 in the manuscript.
Title: Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease
receiving different sequences of first- and second-line biologic treatments: findings from
ROTARY
Version: 0 Date: 19 Dec 2023
Reviewer's report:
In a clinical practice setting, patients tend to worry about complications that they might develop
from the prescribed medication. Providers have to balance patient care by assessing both efficacy
and safety. Efficacy is less than 50% for almost all advanced treatment options and therefore,
patients tend to get exposed to at least two medications. How sequence impacts long term
efficacy and safety has been of great interest to providers.
In this manuscript, adverse outcomes are described in treatment sequence and findings are
notable and include risk of dysplasia and CRC.
One limitation is that the evaluable sample size is different for each of the 6 sequences. Authors
do not comment about this in the limitation section lines 333 to 343 in the manuscript.
Please review this paper.
user
Title: Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease
receiving different sequences of first- and second-line biologic treatments: findings from
ROTARY
Version: 0 Date: 19 Dec 2023
Reviewer's report:
In a clinical practice setting, patients tend to worry about complications that they might develop
from the prescribed medication. Providers have to balance patient care by assessing both efficacy
and safety. Efficacy is less than 50% for almost all advanced treatment options and therefore,
patients tend to get exposed to at least two medications. How sequence impacts long term
efficacy and safety has been of great interest to providers.
In this manuscript, adverse outcomes are described in treatment sequence and findings are
notable and include risk of dysplasia and CRC.
One limitation is that the evaluable sample size is different for each of the 6 sequences. Authors
do not comment about this in the limitation section lines 333 to 343 in the manuscript.
assistant